Kura Oncology (NASDAQ:KURA) announced its quarterly earnings data on Monday. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01), Bloomberg Earnings reports.
Kura Oncology (NASDAQ:KURA) opened at $23.25 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48. Kura Oncology has a 52-week low of $5.90 and a 52-week high of $24.02.
An institutional investor recently bought a new position in Kura Oncology stock. State Street Corp bought a new stake in Kura Oncology Inc (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 149,749 shares of the company’s stock, valued at approximately $1,394,000. State Street Corp owned about 0.70% of Kura Oncology at the end of the most recent reporting period. Institutional investors own 64.65% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.